

A *UTF1*-based selection system for stable homogeneously pluripotent human embryonic stem cell cultures

Shen Mynn Tan¹, Siew Tein Wang², Hannes Hentze² and Peter Dröge^{1,*}

¹School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, 637551 and ²ES Cell International Pte Ltd, 11 Biopolis Way, #05-06 Helios, 138667 Singapore

Received March 2, 2007; Revised August 7, 2007; Accepted August 24, 2007

ABSTRACT

Undifferentiated transcription factor 1 (UTF1) was identified first in mouse embryonic stem cells and is also expressed in human embryonic and adult stem cells. UTF1 transcription ceases at the onset of differentiation, which clearly distinguishes it from less sensitive pluripotency markers, such as *Oct4* or *Nanog*. We present here two transgenic hESC lines, named ZUN. Each line harbors one copy of the *UTF1* promoter/enhancer driving a resistance gene and yielded highly homogeneous cultures under selection pressure, with a larger proportion of *Oct4* and *Sox2* positive cells. While ZUN cultures, like parental HUES8 cultures, retained the capacity to differentiate into tissues of all three germ layers using a SICD mouse teratoma model, they surprisingly exhibited an increased refractoriness to various differentiation cues *in vitro*. Together with its small size of only 2.4 kb for the entire cassette, these features render our selection system a powerful novel tool for many stem cell applications and human somatic cell reprogramming strategies.

INTRODUCTION

The transcriptional co-activator 'undifferentiated transcription factor 1' (UTF1) is expressed in both mouse and human embryonic stem cells (mESCs and hESCs, respectively) (1–3). UTF1 interacts with ATF-2 and TBP-containing complexes, and seems to be involved in cell proliferation control (4,5). *UTF1* is regarded as one of the most important pluripotency marker genes defining the hESC niche (6,7). Importantly, its transcriptional regulation is very sensitive to differentiation cues and switched off faster and with a larger magnitude than either *Oct4* or *Sox2* during embryoid body formation from both mouse and human ESCs (8–10). A similar response is seen when mouse embryonic carcinoma (EC) and mESCs were

triggered to differentiate by retinoic acid (RA) (11,12). In a comparison of hESCs cultured in medium containing either fetal calf serum or defined serum replacement, *UTF1* was found to be downregulated to a larger extent in serum medium compared to *Oct4* or *Sox2*, suggesting strongly that it is a very reliable marker for early differentiation (13). Furthermore, RNA interference (RNAi) of *Oct4* transcripts in mESCs has been shown to cause downregulation of *UTF1* transcripts (14), and more than 90% of all cells in undifferentiated mESC populations stain positively for both these markers (15). These two experiments further allude to the prevalence of UTF1 and *Oct4* co-expression in undifferentiated ESCs.

Human embryonic stem cell cultures are always heterogeneous and usually contain a subset of less pluripotent and, hence, more differentiated cells (16–18). This is also true for mouse and medaka ESCs (19,20). It was shown that the presence of minor populations of differentiated cells compromises the pluripotency of entire stem cell cultures (21). These features represent a severe problem for many hESC applications which can be addressed either via fluorescence-activated cell sorting (FACS) in order to isolate pluripotent hESCs or by antibiotic selection as a means to eliminate differentiating cells.

FACS strategies generally utilize transgenes, such as *EGFP*, under the control of genetic elements of a pluripotency marker. For example, mouse *Rex1-EGFP* and *Oct4-EGFP* combinations have been used in hESCs to screen for undifferentiated cells via flow cytometry (17,22,23). A recent improvement in semi-automated FACS and clonal recovery utilized a mouse *Oct4-EGFP* construct to sort for pluripotent hESCs (24). However, this procedure has to be repeated routinely in order to ensure more homogeneous hESC cultures over longer periods of time.

Antibiotic selection has the advantage of being less intrusive to hESCs. Expression of the neomycin resistance (*Neo*) gene and G418 antibiotic selection, along with *EGFP* expression, have been shown to be compatible with

*To whom correspondence should be addressed. Tel: +65 6316 2809; Fax: +65 6791 3856; Email: pdroge@ntu.edu.sg or pdroege2001@yahoo.de

hESC pluripotency (23,25). In the mouse, the *Oct4-Neo* combination has been used to isolate ES and EC cell lines from embryos. (19,21,26). Thus far, only one report utilized the twin markers of *EGFP* and *Neo* driven by an *Oct4* promoter for the maintenance of pluripotency in hESCs (22). However, the ability to select against partially differentiated cells as well as the derivation of more homogeneous pluripotent hESC cultures was not established in these studies.

Here we demonstrate that *UTF1* is an exceptionally sensitive pluripotency marker. We found that *M1*, a genetic element comprising a conserved octamer sequence important for *Nanog* expression (27), is also present and functional in the *UTF1* 3' enhancer, but not in the UTR of *Oct4* or *Sox2*. As a representative example, we present two stable ZUN hESC lines in which *Neo* is under the control of *UTF1* promoter/enhancer. Application of G418 selection results in ablation of differentiated hESCs and homogeneously pluripotent ZUN cultures, containing a significantly larger number of *Oct4* and *Sox2* positive cells compared to parental cultures. While ZUN cultures retain the capacity to differentiate into progenitors of all three germ layers *in vivo*, they surprisingly exhibited an increased refractoriness to differentiation cues under various culture conditions.

MATERIALS AND METHODS

Plasmids

The full-length human *UTF1* gene was amplified from HeLa genomic DNA using primers UTF1-F (CCGGAATTCAGCGCCAGGACCGACCCCTTA) and UTF1-R (TGCTCTAGAGGGTTCAGCACTTCTCCTGCCTC) via PCR. The product was cleaved with *EcoRI* and *XbaI*, and ligated into phagemid *pTZ-18R*. The *UTF1* coding sequence was subsequently replaced with that of *EGFP* or *Neo* in the following way. *KpnI* and *NcoI* restriction sites were introduced between the end of the *UTF1* promoter and before the ATG codon by amplifying the promoter region of *pTZ-UTF1* via PCR with primers UTF1-F and UTF1-MR (CGGGGTACCCCGGGGCTGGGGCGCGG). The resulting fragment was cleaved with *EcoRI* and *NcoI*, and ligated to a cleaved *pCMV-EGFP* which replaces the CMV promoter. The plasmid was then digested with *EcoRI* and *BsrGI* to produce an (*EcoRI*) *UTF1*promoter-*EGFP* (*BsrGI*) sticky-ended fragment. *pTZ-UTF1* was used as a PCR template to amplify a segment of the *UTF1* 3' UTR region and inserting a *BsrGI* RE site near the end of *UTF1* transcription unit using primers UTF1-MF (AGCTGTACAAGTGAGTCCCGGCTGCGGC) and UTF1-BR (AGAATACTCAAGCTATGCATCCAAC). This produced another *BsrGI*-*BamHI* sticky-ended 1 kb fragment. *pTZ-UTF1* was then digested with *EcoRI* and *BamHI*, and this 3.2 kb fragment was ligated to the above two 1 kb fragments, yielding *pTZ-UTF1-EGFP*. The *Neo* gene was amplified with flanking *KpnI* and *BsrGI* RE sites via PCR with *pPGK-Neo* as template and Neo-F (CTGGGTACCCCATGATTGAACAAGATGG) and Neo-R (ACTGTGTAATCAGAAGAAGTCTCGTCAAGAA) primers.

The *pTZ-UTF1-EGFP* backbone was digested with *KpnI* and *BsrGI* to remove *EGFP*, and ligated with the cleaved *Neo* fragment to yield *pTZ-UTF1-Neo*. The promoter-less version of *pTZ-UTF1-EGFP* was generated using *EcoRI* and *KpnI* to remove the *UTF1* promoter. The ends were blunted using Klenow Fragment (NEB) followed by self-ligation. The enhancer-less version of *pTZ-UTF1-EGFP* was generated using *PstI* to remove the *UTF1* enhancer followed by self-ligation.

pTZ-UTF1-EGFP was used as template to introduce the mutant M1 sequence (GTAGTGGT; original sequence GTCTGGGT) (27). Flanking arms 200 bp from M1 were amplified using two primer pairs, UTF1-M1F (GACCCA GGAGTAGCATG) and UTF1-M1mR (CTAGGCCCA CCACTACCAGAGCCAC) (near the 5' *XcmI* RE site), and UTF1-M1mF (GTGGCTCTGGTAGTGGTGGGC CTAG) and UTF1-M1R (CATTGTTATGCTAGCGG) (near the 3' *NheI* RE site). These were combined via assembly PCR using UTF1-M1F and UTF1-M1R as primers. The resulting 370 bp fragment was digested with *XcmI* and *NheI*, and ligated to a similarly cleaved *pTZ-UTF1-EGFP* in order to replace the original M1 sequence.

Plasmids were amplified in *Escherichia coli* strain DH5 α . We used standard PCR conditions with *Pfu* polymerase (Promega). Restriction enzymes were from New England Biolabs.

Cell culture, transfection and differentiation

F3 human foreskin fibroblasts (28), A549 and HeLa carcinoma cell lines were cultured according to standard procedures. hESC line hES2 (karyotype: 46XX) was obtained from ES Cell International Pte Ltd. HUES8 (karyotype: 46XY) and HUES9 (karyotype: 46XX, inv9) was provided by the Harvard Stem Cell Institute. hESCs were cultured on G418-resistant MEFs (PMEF-N, Chemicon), as previously described (29,30).

F3, A549 and HeLa cells were transfected with 10 μ g of reporter plasmid via electroporation as described previously (31). hESCs were transfected with 2 μ g of reporter plasmid and Effectene (Qiagen) as described previously (29).

Differentiation medium was prepared by removing basic fibroblast growth factor and exchanging knockout serum replacement with fetal bovine serum (all three from Gibco). Spontaneous differentiation was conducted on matrigel (BD Biosciences) or gelatin surfaces without MEFs. Induced differentiation on MEFs was conducted either with 10 μ M (RA) or 1% (DMSO) (Sigma) which was added to differentiation medium (32). Embryoid body formation was induced by plating hESCs onto low-cell binding plates (Nunc).

SCID mouse teratoma assay

To test the differentiation potential of hESC lines *in vivo*, serially passaged hESCs were manually harvested and injected as clumps with an approximate cell dose of 2–4 $\times 10^6$ cells in a volume of 50 μ l into the quadriceps of the right hind limb of a male SCID mouse (3 mice/hESC line). Mice were maintained under controlled conditions

in accordance with the National Institutes of Health (NIH) and National Advisory Committee for Laboratory Animal Research (NACLAR) guidelines, and with approval of the Biopolis Institutional Animal Care and Use Committee (Biopolis IACUC approval 050008, National University of Singapore Institutional Review Board 05-020). Teratoma formation was monitored visually using a simple grading system that was confirmed by caliper measurements (grade 0—no detectible enlargement, grade 1—enlargement just detectible, grade 2—obvious enlargement, grade 3—enlargement impedes locomotion). When teratomas reached grade 3 (after 6–8 weeks), teratomas weighing 1–2 g were excised, fixed (Bouin's solution), paraffin-embedded, sectioned and histologically analyzed following staining with hematoxylin and eosin. Additionally, teratomas were assessed by a pathologist at the Department of Pathology, National University of Singapore.

Characterization of ZUN hESC lines

ZUN cell lines were generated by transfecting HUES8 cells using Effectene with *pTZ-UTF1-Neo*. Individual colonies were mechanically expanded in the presence of G418 (500 µg/ml). Cloning efficiency was 10^{-5} , with four stable cell lines generated, of which only two contained the full-length *UTF1-Neo* cassette. These two lines were analyzed here and labeled as 'ZUN'. Karyotyping via Giemsa staining was performed by Cytogenetics Lab, KK Women's and Children's Hospital, Singapore. 50 µl of BrdU/Colcemid (50:50) mixture was added to an 80% confluent 35 mm dish containing hESCs with 2 ml of medium the night before staining and analysis. Transgenic genomic inserts in both cell lines were sequenced from correctly sized genomic PCR products amplified using standard *Taq* PCR protocols and UTF1-F and UTF1-R primers. Southern blotting was performed as previously described (33), with 10 µg of isolated genomic DNA digested with EcoRI. *Neo* was detected using a 32 P-labeled *Neo* probe. WST-1 cell proliferation assays were conducted using manufacturer protocols (Roche). Briefly, 3×10^4 cells were seeded onto each MEF-layered 96-well at day 0. WST-1 reagent was added to the wells for 30 min the next day, and 440 nm readings were recorded using a standard photoplate reader. This was repeated for a total of 4 days with different plates. Each cell line had five replicates per time-point. Alkaline phosphatase staining and TRA-1-60/TRA-1-81 surface marker immunostaining (visualized with FITC) were conducted using manufacturer protocols (Chemicon). Flow cytometry of surface markers, Oct4 and Sox2 was performed as previously described (29), with pre-incubation of primary and FITC-conjugated secondary antibodies (Santa Cruz).

Quantitative real-time PCR

Total RNA was recovered from cell pellets (Qiagen) and cDNA was synthesized via the SSII reverse transcriptase kit, primed with oligo dTs (Invitrogen). SYBR Green qRT-PCR (Qiagen) was conducted using the 7500 real-time PCR System and results analyzed using sequence

detection software (SDS) version 1.2.3 (Applied Biosystems). All experiments had at least biological duplicates and assay triplicates, and results were analyzed via the $\Delta\Delta$ Ct method using GAPDH as the housekeeping transcript. Primers used were as follows: GAPDH (CCCCTCCCTCCACCTTTGAC and CTCCCCTCTTCAAGGGTCT), Nanog (AGTCCCAAAGGCAAACAACCCACTC and ATCTGCTGGAGGCTGAGGTA TTTCTGTCTC) (6), Oct4 (CTTGCTGCAGAAGTGGG TGGAGGAA and CTGCAGTGTGGGTTTCGGGCA) (1), Sox2 (ATGCACCGCTACGACGTGA and CTTTT GCACCCCTCCCATTT) (1), UTF1 (AGCAGATCCGG AAGCTCATGGG and TCCTCGGGGATGCAGGTG), UTF1-Neo (GGGTACCCCATGATTGAACA and CAGGTCGGTCTTGACAAAAG), Sox9 (GAAGCTCGC GGACCAGTA and CGTTCTTCACTTCCCTC), Nestin (CGTTGGAACAGAGGTTGGAG and GAGC GACTGGCTCTGTAGG), ID2 (CTGGACTCGCA TCCCCTAT and CACACAGTGTCTTGTCTGTA), HAND1 (TGCCTGAGAAAGAGAACCAG and ATGGCAGGATGAACAAACAC) (9), IGF2 (TCCTC CCTGGACAATCAGAC and AGAAGCACCAGCAT CGACTT) (9), α 1AT (AGACCCTTTGAAGTCAAG GACACCG and CCATTGCTGAAGACCTTAGTG ATGC) (34).

RESULTS

UTF1 is a sensitive pluripotency marker for hESCs

We evaluated first the sensitivity of *UTF1* expression with respect to induced differentiation using quantitative real-time PCR (qRT-PCR). Various hESC lines were triggered to differentiate via retinoic acid (RA) or dimethyl sulfoxide (DMSO) treatment. The results show that this almost completely abolished *UTF1* expression; a response that was not observed for *Nanog* and *Oct4* (Figure 1A). We next generated the following three *UTF1* transgenic constructs: *pTZ-UTF1*, *pTZ-UTF1-EGFP* and *pTZ-UTF1-Neo* (Figure 1B). In addition, three variants of *pTZ-UTF1-EGFP* were designed: one without the minimal 5' promoter, one lacking the 3' enhancer, and one containing an altered *MI* sequence. The *MI* octamer sequence was found to be conserved in the *Nanog* promoter of many species (27), and we identified it recently upstream of the Oct4/Sox2 binding site within the 3' *UTF1* enhancer.

The results demonstrate hESC-specific expression of the full-length *pTZ-UTF1-EGFP* after transfection into various human cell lines and hESC line HUES8 (Figure 1C). We next introduced the three *pTZ-UTF1-EGFP* versions into HUES8 cells and showed that the 5' promoter and 3' enhancer regions were essential for EGFP expression (Figure 1C). In addition, the altered *MI* element reproducibly led to a significantly smaller number of EGFP expressing hESCs, which is similar in magnitude to its reported effect on *Nanog* transcription (27). Together, these data confirm that *UTF1* transcription is a very sensitive pluripotency marker specific for hESCs and suggests that its regulation in hESCs involves *MI*-binding factors in addition to Oct4 and Sox2.




Figure 1. UTF1 expression in hESCs. (A) qRT-PCR Expression analysis of RA- (for 12 days) and DMSO-induced (for 7 days) differentiation in hESCs, normalized to that of respective undifferentiated hESC lines, with two biological replicates for each sample. (B) Schematic drawing of vectors. Full-length *UTF1* was cloned into phagemid *pTZ-18R* yielding *pTZ-UTF1*. Its coding region was subsequently replaced with enhanced green fluorescent protein (*EGFP*) or neomycin (*Neo*), yielding *pTZ-UTF1-EGFP* and *pTZ-UTF1-Neo*, respectively. Red text indicates alterations in *pTZ-UTF1-EGFP*. (C) Flow cytometry of *UTF1*-driven EGFP expression in various cell lines following transient transfection of *pTZ-UTF1-EGFP*. Transfection efficiencies were normalized to those determined in parallel using *pCMV-EGFP* and are the average of three biological replicates. See Supplementary Figure S7 for representative dot plots.

Characterization of transgenic *pTZ-UTF1-Neo* hESC lines

We established stable *pTZ-UTF1-Neo* cell lines from HUES8 cells via random genomic transgene insertion. Two single-copy lines with normal karyotype, dubbed ZUN1 and ZUN2, were used in subsequent experiments (Supplementary Figure S1). Careful characterization of both lines revealed that they have similar proliferation rates (Supplementary Figure S2), exhibit comparable alkaline phosphatase (AP) staining patterns (Supplementary Figure S3), and express *Nanog* at a similar level as parental HUES8 cells (Figure 2A). However, an elevated level of *Oct4*, *Sox2* and *UTF1* in ZUN cultures was reproducibly detected by qRT-PCR (Figure 2B). This correlation of expression supports the notion that the control of *UTF1* involves factors Oct4 and Sox2, but most likely not Nanog (35).




Figure 2. Characterization of ZUN hESC lines. (A) Expression analysis of ZUN hESCs. qRT-PCR comparison of pluripotency markers across the three hESC cultures normalized to HUES8 samples, performed with biological triplicates. (B) Oct4 and Sox2 expression analysis of ZUN hESCs. Percentage of hESCs expressing Oct4 and Sox2. ZUN cultures consist of significantly more Oct4- and Sox2-expressing cells compared to HUES8, based on the two-tailed paired Student's *t*-test (P -values < 0.05). (C) Surface marker analysis of ZUN hESCs. Percentage of positively stained hESCs for TRA-1-60 and TRA-1-81. Both ZUN lines consist of significantly more positively stained cells compared to parental HUES8, based on the two-tailed paired Student's *t*-test (P -values < 0.05). (D) qRT-PCR analysis of removal and restoration of G418 selection pressure on ZUN1 and ZUN2 cultures. ZUN lines were cultured in the presence of G418 for 90 days (+G418); G418 removed for 30 (-G418) or 60 (-/-G418) days; G418 removed for 30 days and re-introduced for 30 days (-/+G418). Expression levels were normalized to +G418 values and presented as an average of three experimental repeats.




Figure 3. Differentiation of ZUN hESC lines on Matrigel and Gelatin. (A) Expression analysis of spontaneous differentiation using pluripotency markers. The qRT-PCR of hESCs without MEFs plated on gelatin or matrigel for 12 days was performed with biological triplicates, and presented as expression levels relative to that of respective undifferentiated cell lines. (B) AP staining of hESCs on gelatin and matrigel. Representative phase contrast photomicrographs comparing HUES8 and ZUN cell morphologies on the 12th day and visualization of the ablative effects after 2 days of exposure to G418. Scale bar: 55 μ m.

Flow cytometry revealed that the observed higher level of global *Oct4*, *Sox2* and *UTF1* expression was due to the presence of a larger fraction of cells that express these markers. A statistically significant higher percentage of ZUN cells stained positive for *Oct4* and *Sox2* compared to HUES8 cultures (Figure 2B). We could also demonstrate that ZUN cultures contained more cells which stain positive for surface markers TRA-1-60 and TRA-1-81 (Figure 2C). These results indicate that HUES8 cultures contained more hESCs with a low expression level of pluripotency markers. In contrast, such cells have been ablated in ZUN cultures via G418 selection.

We next analyzed the effect of sequential removal and restoration of G418 selection on both ZUN lines and employed qRT-PCR of pluripotency markers *Nanog*, *Oct4*, *Sox2* and *UTF1* for the detection of the onset of differentiation (9). We also included the transgene *UTF1-Neo* in this analysis because its regulation should be linked to that of the endogenous *UTF1*. The results show that spontaneous differentiation can be detected in cultures during 60 days of G418 withdrawal. This is indicated by the progressive reduction in signals obtained from all markers, with the exception of *Sox2* (Figure 2D). However, upon re-application of antibiotic selection, original expression levels could be restored in these cultures. Using a transgenic hESC line in which *Neo* is expressed from the elongation factor 1 alpha (*EF-1 α*) promoter as a control, we confirmed that G418 withdrawal has no effect on the expression of this set of markers which clearly links this effect to the presence of the *UTF1-Neo* transgene in hESCs (Supplementary Figure S4). Together, these data show that ZUN cultures are more homogeneously pluripotent than the parental cultures and that G418 addition and subsequent ablation of differentiated ZUN cells is required to sustain homogeneous cultures over longer periods of time.

ZUN cultures are refractory to various differentiation cues

We demonstrated above that ZUN cultures are more homogeneously pluripotent than the parental cultures. We were interested, therefore, in investigating the differentiation behavior of ZUN cells. First, we induced differentiation by plating them on matrigel or gelatin without supporting mouse embryonic fibroblasts (MEFs) and in the absence of G418. In the matrigel protocol, HUES8 cells quickly initiated differentiation as indicated by the 5-fold downregulation of our panel of markers (Figure 3A). However, both ZUN lines maintained significantly higher overall expression levels even after 12 days of culture. Similarly, the gelatin protocol induced a 2-fold downregulation of *Oct4* and *UTF1* in HUES8, but not in ZUN populations. We observed further that under these conditions, ZUN cultures have a larger number of colonies consisting of cells which display a more compact morphology that stain stronger for alkaline phosphatase (AP), and a reduced occurrence of differentiating cells at colony edges. Upon subsequent addition of G418 for 2 days, only pluripotent cells that stained for AP survived in ZUN cultures, demonstrating again that differentiating ZUN cells are rapidly and efficiently ablated by G418 selection (Figure 3B).

We analyzed next the effects of RA or DMSO treatment on ZUN cultures in the absence of G418 selection. After 12 and 7 days, respectively, qRT-PCR showed that ZUN cultures exhibited a lower rate of differentiation in comparison to HUES8 cultures (Figure 4A). Notably, *UTF1* and *UTF1-Neo* expression diminished by the largest magnitude among the pluripotency markers. Certain differentiation markers also indicated a slower onset of differentiation in ZUN cultures. HUES8 cultures showed a greater (2- to 10-fold) upregulation of *Sox9*, *Nestin* and *ID2* due to RA treatment, and of *HAND1*, *IGF2* and *Nestin* after exposure to DMSO (Figure 4B). The expression of surface markers of pluripotency,




Figure 4. Differentiation of ZUN hESCs induced by RA and DMSO. (A) Expression analysis of induced differentiation using pluripotency markers. qRT-PCR of hESCs on MEFs induced to differentiate via RA (for 12 days) or DMSO (for 7 days) in differentiation medium. (B) Transcript analysis of induced differentiation using differentiation markers. (C) TRA-1-60 and TRA-1-81 surface marker immunostaining for induced differentiation, comparing HUES8 with ZUN cultures. The bottom row shows a control panel of undifferentiated HUES8 cells stained with secondary antibody only, TRA-1-60 or TRA-1-81 antibodies (left to right). Scale bar: 30 μ m. (D) Transcript analysis after EB formation. qRT-PCR of EBs from hESCs induced to differentiate for 21 days in suspension cultures. The qRT-PCR experiments were performed with biological duplicates, and presented as expression levels relative to that of respective undifferentiated cell lines.

TRA-1-60 and TRA-1-81, complements these transcript analyses, showing that HUES8 cells exhibited a more muted staining pattern compared to ZUN colonies (Figure 4C). These results confirm our conclusion that under various conditions, ZUN cultures exhibit a more robust phenotype against the onset of differentiation than parental cultures.

ZUN cells retain the capacity to differentiate into progenitors of all three germ layers *in vitro* and *in vivo*

The observed phenotype of increased robustness against the onset of differentiation led us to investigate ZUN cultures under long term differentiation conditions. The results show that ZUN and HUES8 cells cultured under RA and DMSO differentiation protocols for 30 days show

similar morphologies and lack of AP staining (Supplementary Figure S5). These cells were completely ablated upon addition of G418, as were those in equally long-term gelatin and matrigel cultures (data not shown). In addition, 21 days of embryoid body formation in suspension cultures caused a significant upregulation of differentiation markers from all three germ layers (Figure 4D). Both ZUN lines and HUES8 show very high expression of *HAND1*, *IGF2* and *ID2* as indicated by the large fold increase relative to their undifferentiated counterparts. They also show relatively high expression of α 1 anti-trypsin (*α 1AT*) and *Sox9*. The morphological characteristics and growth rates of HUES8 and ZUN cell-derived EBs were indistinguishable (Supplementary Figure S6). Furthermore, we showed by a teratoma assay that the parental HUES8 line as well as ZUN1 and




Figure 5. Teratoma formation SCID mice studies. The hESC lines ZUN1 (A), ZUN2 (B) and the parental line HUES8 (C) were injected into the hind leg of male SCID mice, and the teratoma formation was followed by a simple grading system (see Materials and Methods section). When teratomas were full developed (1–2 g tissue weight, 6–8 weeks), they were harvested and processed by routine histological procedures, followed by hematoxylin/eosin staining. (D) Detailed histology of ectodermal (epithelium, neuroectoderm), mesodermal (bone in red, cartilage in blue) and endodermal (glandular structures) structures are shown for each hESC line.

ZUN2 formed tissue of all three germ layers (i.e. ectodermal structures, mesoderm such as cartilage and bone, as well as mesodermal glandular structures) when transplanted into immune-deficient SCID mice (Figure 5). We conclude, therefore, that the robustness which our ZUN cultures displayed against the onset of differentiation induced by various protocols does not compromise their potential to differentiate, like parental cultures, into all three germ layers *in vitro* and *in vivo*.

DISCUSSION

Expression of *UTF1* is controlled by a 5' TATA-less promoter consisting of four GC boxes. The 3' enhancer element harbors a twin octamer sequence where the synergistic binding of Oct4 and Sox2 is essential for *UTF1* expression in both mouse and human ESCs (8,35). Sp1-like transcription factors that bind to GC boxes present in the *UTF1* promoter are most likely involved in the regulation of *UTF1*, since they are regarded as regulators of embryonic development in vertebrates (36) and shown to be involved in the transcriptional control of both *Oct4* and *Nanog* (37,38). We showed here that *UTF1* is indeed expressed in hESCs, but not in human primary fibroblasts and carcinoma cell lines. Further, both 5' promoter and 3' enhancer are needed for expression. A novel finding is that an octamer sequence (*MI*) which is conserved in the *Nanog* promoter

of many species (27) is also present upstream of the analogous human *Oct4/Sox2* cognate sequence in the 3' *UTF1* enhancer. The fact that *MI* mutations resulted in equally muted expression levels of *UTF1* and *Nanog*, strongly suggests that similar *MI*-binding factor(s) are involved in the control of both pluripotency marker genes. Our results also confirm previous reports showing that endogenous *UTF1* is downregulated faster than *Oct4* or *Nanog* at the onset of differentiation to nearly undetectable levels. In addition, detailed analysis of SymAtlas data from the Genomics Institute of the Novartis Research Foundation showed that both *UTF1* and *Nanog* expression are greatly diminished at day 8.5 of mouse embryo formation, unlike *Oct4* or *Sox2* (<http://symatlas.gnf.org>). Together, these results firmly establish *UTF1* as a sensitive and reliable pluripotency marker for hESCs.

Recent reports revealed that *UTF1* is also an important marker expressed in other stem cell types. For example, spermatogonial stem cells isolated from adult mouse testis were shown to exhibit features reminiscent of pluripotent ESCs. These cells express *Oct4*, *Nanog*, *Rex1* and *UTF1* and, interestingly, also downregulate *UTF1* significantly faster than these other markers upon embryoid body formation (39). Further, pluripotent stem cells derived from re-programmed primary mouse fibroblasts through co-expression of transgenes encoding Oct4, Sox2, c-Myc and Klf4 also express *UTF1*. It is noteworthy that the expression level of *UTF1* in pluripotent stem cells derived from different sources is always more tightly linked with

that of the key marker *Oct4*, and not with other markers like *Cripto* or *Nanog* (40). These data, in conjunction with results presented here, indicate that our *UTF1*-based selectivity tool should be widely applicable to select for pluripotent human stem cell lines derived from different sources.

We demonstrated that the control of both endogenous and exogenous *UTF1* in ZUN cells is linked, as expected, and that *UTF1*-driven *Neo* expression in hESCs in conjunction with G418 selection can be used to efficiently ablate differentiating cells in standard culture conditions. This resulted in ZUN cultures which display a higher global expression level of key pluripotency markers. We showed that this elevated level is most likely due to an increase in the fraction of Oct4 and Sox2 positive hESCs. Furthermore, the number of cells staining positive for surface markers TRA-1-60 and TRA-1-81 was also elevated which, if taken together, indicates that ZUN cultures are more homogeneously pluripotent than the parental cultures (Figure 2A–C). Upon removal of selection pressure from ZUN cultures, the overall expression level of these markers declined, which indicates loss of pluripotency and, consequently, more heterogeneous hESC cultures. Interestingly, the absence of selection pressure for 60 days did not cause widespread silencing of the exogenous *UTF1-Neo*. This enabled us to add G418 only periodically in order to select against differentiating hESCs in ZUN cultures. Hence, the *UTF1* promoter/enhancer combination could be a generally applicable control element for sustained expression of transgenes in pluripotent hESCs, even in the absence of selection.

We showed that the generation of ZUN lines harnessed the sensitivity of *UTF1* as a pluripotency marker which resulted in rapid and efficient ablation of differentiating cells. An unexpected finding was the refractoriness of ZUN cultures to the onset of differentiation. We attribute this phenotype to the increased fraction of pluripotent hESCs in homogeneous ZUN cultures compared to typical, more heterogeneous hESC cultures. Given the propensity for heterogeneous cultures to spontaneously differentiate (21), the increased stability of human stem cell cultures with respect to the uniformity in pluripotency combined with efficient ablation of differentiating cells offered by the ZUN system could significantly improve large scale growth for many future hESCs applications. In addition, ZUN cultures show a higher expression of pluripotency markers when compared to HUES8 cultures following thawing after standard slow cooling cryopreservation procedures (data not shown), thereby counteracting a reported negative effect associated with cryopreservation (41).

An intrinsic advantage of the *UTF1*-based selection system over other pluripotency marker-based strategies is its enhanced sensitivity towards many differentiation pathways. Although the well-characterized pluripotency marker *Oct4* has been a component in strategies for both mouse and human ESCs (21,22), the use of *Oct4* in this context can be problematic. Apart from being less sensitive to the onset of differentiation, its expression level is also very tightly controlled. A less than 2-fold increase in *Oct4* expression alone leads to differentiation

into primitive endodermal and mesodermal lineages in mouse ESCs (42). This implies that the *Oct4-Neo* system is potentially less sensitive to these differentiation pathways, and, thus, will not be able to efficiently ablate cells that are undergoing differentiation into these lineages. In addition, the <2 kb length of the entire human *UTF1* promoter/enhancer element represents a significant advantage for genetic manipulation of hESCs, or other human cell types, if one compares this to an unwieldy 8 kb of the *Oct4* control element.

Our ZUN system has a large range of potential applications. In its current context as a stable transgene in hESCs, it can be used for the maintenance of homogeneously pluripotent cultures. In combination with gene targeting technologies, this application can be upscaled to meet the larger cell quantities ultimately needed for stem cell-based therapies. ZUN lines can also be employed to screen and characterize synthetic factors, media components or surface matrices that permit maintenance of pluripotency, and it can be used to test 3D scaffolds or aid in the derivation of new hESC lines.

As indicated above, the ZUN system shows potential in selection protocols in order to isolate adult stem cells from primary cultures. It can also be used in hESCs in conjunction with cell differentiation strategies as a component of positive-negative selection. The system can also function as a tool in somatic cell reprogramming experiments to identify successfully reprogrammed pluripotent cells. It can also be used to improve future human somatic cell nuclear transfer protocols. With our first demonstration of its utility here and its many possible applications, we envision that our ZUN system will become a valuable selectivity tool for many facets of stem cell research.

SUPPLEMENTARY DATA

Supplementary Data are available at NAR Online.

ACKNOWLEDGEMENTS

We thank R.J. Zhou for help with the Southern blot analysis, C.-T. Lee for the construction of *pTZ-UTF1-EGFP(M1)* and K. Neef for hESC line EPN14. Special thanks go to C.A. Davey for critical comments on the manuscript. Funding to pay the Open Access publication charges for this article was provided by NTU special investigator grant.

Conflict of interest statement. None declared.

REFERENCES

- Ginis,I., Luo,Y., Miura,T., Thies,S., Brandenberger,S., Gerecht-Nir,S., Amit,M., Hoke,A., Carpenter,M.K. *et al.* (2003) Differences between human and mouse embryonic stem cells. *Dev. Biol.*, **269**, 360–380.
- Brimble,S.N., Zeng,X., Weiler,D.A., Luo,Y., Liu,Y., Lyons,I.G., Freed,W.J., Robins,A.J., Rao,M.S. *et al.* (2004) Karyotypic stability, genotyping, differentiation, feeder-free maintenance, and gene expression sampling in three human embryonic stem cell lines derived prior to August 9, 2001. *Stem Cells Dev.*, **13**, 585–597.

3. Sun, Y., Li, H., Liu, Y., Shin, S., Mattson, M.P., Rao, M.S. and Zhan, M. (2007) Cross-species transcriptional profiles establish a functional portrait of embryonic stem cells. *Genomics*, **89**, 22–35.
4. Fukushima, A., Okuda, A., Nishimoto, M., Seki, N., Hori, T.A. and Muramatsu, M. (1998) Characterization of functional domains of an embryonic stem cell coactivator UTF1 which are conserved and essential for potentiation of ATF-2 activity. *J. Biol. Chem.*, **273**, 25840–25849.
5. Nishimoto, M., Miyagi, S., Yamagishi, T., Sakaguchi, T., Niwa, H., Muramatsu, M. and Okuda, A. (2005) Oct-3/4 maintains the proliferative embryonic stem cell state via specific binding to a variant octamer sequence in the regulatory region of the *UTF1* locus. *Mol. Cell. Biol.*, **25**, 5084–5094.
6. Bhattacharya, B., Miura, T., Brandenberger, R., Mejido, J., Luo, Y., Yang, A.X., Joshi, B.H., Ginis, L., Thies, R.S. *et al.* (2004) Gene expression in human embryonic stem cell lines: unique molecular signature. *Blood*, **103**, 2956–2964.
7. Trounson, A. (2006) The production and directed differentiation of human embryonic stem cells. *Endocr. Rev.*, **27**, 208–219.
8. Nishimoto, M., Fukushima, A., Okuda, A. and Muramatsu, M. (1999) The gene for the embryonic stem cell coactivator *UTF1* carries a regulatory element which selectively interacts with a complex composed of Oct-3/4 and Sox-2. *Mol. Cell. Biol.*, **19**, 5453–5465.
9. Cai, J., Chen, J., Liu, Y., Miura, T., Luo, Y., Loring, J.F., Freed, W.J., Rao, M.S. and Zeng, X. (2006) Assessing self-renewal and differentiation in human embryonic stem cell lines. *Stem Cells*, **24**, 516–530.
10. Wei, C.L., Miura, T., Robson, P., Lim, S.K., Xu, X.Q., Lee, M.Y., Gupta, S., Stanton, L., Luo, Y. *et al.* (2005) Transcriptome profiling of human and murine ESCs identifies divergent paths required to maintain the stem cell state. *Stem. Cells*, **23**, 166–185.
11. Eifert, C., Sangster-Guity, N., Yu, L.M., Chittur, S.V., Perez, A.V., Tine, J.A. and McCormick, P.J. (2006) Global gene expression profiles associated with retinoic acid-induced differentiation of embryonal carcinoma cells. *Mol. Reprod. Dev.*, **73**, 796–824.
12. Ivanova, N., Dobrin, R., Lu, R., Kotenko, I., Levorse, J., DeCoste, C., Schafer, X., Lun, Y. and Lemischka, I.R. (2006) Dissecting self-renewal in stem cells with RNA interference. *Nature*, **442**, 533–538.
13. Skottman, H., Stromberg, A.-M., Matilainen, E., Inzunza, J., Hovatta, O. and Lahesmaa, R. (2005) Unique gene expression signature by human embryonic stem cells cultured under serum-free conditions correlates with their enhanced and prolonged growth in an undifferentiated stage. *Stem Cells*, **24**, 151–167.
14. Sen, G., Wehrman, T.S., Myers, J.W. and Blau, H.M. (2004) Restriction enzyme-generated siRNA (REGS) vectors and libraries. *Nat. Genet.*, **36**, 183–189.
15. Hoof, D.V., Passier, R., Oostwaard, D.W.-V., Pinkse, M.W.H., Heck, A.J.R., Mummery, C.L. and Krijgsveld, J. (2006) A quest for human and mouse embryonic stem cell-specific proteins. *Mol. Cell Proteomics*, **5**, 261–273.
16. Amit, M., Carpenter, M.K., Inokuma, M.S., Chiu, C.P., Harris, C.P., Waknitz, M.A., Itskovitz-Eldor, J. and Thomson, J.A. (2000) Clonally derived human embryonic stem cell lines maintain pluripotency and proliferative potential for prolonged periods of culture. *Dev. Biol.*, **227**, 271–278.
17. Eiges, R., Schuldiner, M., Drukker, M., Yanuka, O., Itskovitz-Eldor, J. and Benvenisty, N. (2001) Establishment of human embryonic stem cell-transfected clones carrying a marker for undifferentiated cells. *Curr. Biol.*, **11**, 514–518.
18. Stewart, M.H., Bosse, M., Chadwick, K., Menendez, P., Bendall, S.C. and Bhatia, M. (2006) Clonal isolation of hESCs reveals heterogeneity within the pluripotent stem cell compartment. *Nat. Methods*, **3**, 807–815.
19. McWhir, J., Schnieke, A.E., Ansell, R., Wallace, H., Colman, A., Scott, A.R. and Kind, A.J. (1996) Selective ablation of differentiated cells permits isolation of embryonic stem cell lines from murine embryos with a non-permissive genetic background. *Nat. Genet.*, **14**, 223–226.
20. Hong, Y., Winkler, C. and Schartl, M. (1996) Pluripotency and differentiation of embryonic stem cell lines from the medakafish (*Oryzias latipes*). *Mech. Dev.*, **60**, 33–44.
21. Mountford, P., Nichols, J., Zevnik, B., O'Brien, C. and Smith, A. (1998) Maintenance of pluripotential embryonic stem cells by stem cell selection. *Reprod. Fert. Dev.*, **10**, 527–533.
22. Zwaka, T.P. and Thomson, J.A. (2003) Homologous recombination in human embryonic stem cells. *Nat. Biotechnol.*, **21**, 319–321.
23. Gerrard, L., Zhao, D., Clark, A.J. and Cui, W. (2005) Stably transfected human embryonic stem cell clones express OCT4-specific green fluorescent protein and maintain self-renewal and pluripotency. *Stem Cells*, **23**, 124–133.
24. Hewitt, Z., Forsyth, N.R., Waterfall, M., Wojtacha, D., Thomson, A.J. and McWhir, J. (2006) Fluorescence-activated single cell sorting of human embryonic stem cells. *Cloning Stem Cells*, **8**, 225–234.
25. Liu, Y.P., Dovzhenko, O.V., Garthwaite, M.A., Dambaeva, S.V., Durning, M., Pollastrini, L.M. and Golos, T.G. (2004) Maintenance of pluripotency in human embryonic stem cells stably over-expressing enhanced green fluorescent protein. *Stem Cells Dev.*, **13**, 636–645.
26. Gallagher, E.J., Lodge, P., Ansell, R. and McWhir, J. (2003) Isolation of murine embryonic stem and embryonic germ cells by selective ablation. *Transgenic Res.*, **12**, 451–460.
27. Rodda, D.J., Chew, J.L., Lim, L.H., Loh, Y.H., Wang, B., Ng, H.H. and Robson, P. (2005) Transcriptional regulation of *nanog* by OCT4 and SOX2. *J. Biol. Chem.*, **280**, 24731–24737.
28. Amit, M., Margulets, V., Segev, H., Shariki, K., Laevsky, I., Coleman, R. and Itskovitz-Eldor, J. (2003) Human feeder layers for human embryonic stem cells. *Biol. Reprod.*, **68**, 2150–2156.
29. Tan, S.M. and Dröge, P. (2005) Comparative analysis of sequence-specific DNA recombination systems in human embryonic stem cells. *Stem Cells*, **23**, 868–873.
30. Cowan, C.A., Klimanskaya, I., McMahon, J., Atienza, J., Witmyer, J., Zucker, J.P., Wang, S., Morton, C.C., McMahon, A.P. *et al.* (2004) Derivation of embryonic stem-cell lines from human blastocysts. *N. Engl. J. Med.*, **350**, 1353–1356.
31. Corona, T., Bao, Q., Christ, N., Schwartz, T., Li, J. and Dröge, P. (2003) Activation of site-specific DNA integration in human cells by a single chain integration host factor. *Nucleic Acids Res.*, **31**, 5140–5148.
32. Brandenberger, R., Wei, H., Zhang, S., Lei, S., Murage, J., Fisk, G.J., Li, Y., Xu, C., Fang, R. *et al.* (2004) Transcriptome characterization elucidates signaling networks that control human ES cell growth and differentiation. *Nat. Biotechnol.*, **22**, 707–716.
33. Christ, N. and Dröge, P. (2002) Genetic manipulation of mouse embryonic stem cells by mutant λ integrase. *Genesis*, **32**, 203–208.
34. Schuldiner, M., Yanuka, O., Itskovitz-Eldor, J., Melton, D.A. and Benvenisty, N. (2000) Effects of eight growth factors on the differentiation of cells derived from human embryonic stem cells. *Proc. Natl Acad. Sci. USA*, **97**, 11307–11312.
35. Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G., Kumar, R.M., Murray, H.L. *et al.* (2005) Core transcriptional regulatory circuitry in human embryonic stem cells. *Cell*, **122**, 947–956.
36. Zhao, C. and Meng, A. (2005) Sp1-like transcription factors are regulators of embryonic development in vertebrates. *Develop. Growth Differ.*, **47**, 201–211.
37. Yang, H.M., Do, H.J., Oh, J.H., Kim, J.H., Choi, S.Y., Cha, K.Y., Chung, H.M. and Kim, J.H. (2005) Characterization of putative cis-regulatory elements that control the transcriptional activity of the human *Oct4* promoter. *J. Cell Biochem.*, **96**, 821–830.
38. Wu, D.Y. and Yao, Z. (2006) Functional analysis of two Sp1/Sp3 binding sites in murine *Nanog* gene promoter. *Cell Res.*, **16**, 319–322.
39. Guan, K., Nayernia, K., Maier, L.S., Wagner, S., Dressel, R., Lee, J.H., Nolte, J., Wolf, F., Li, M. *et al.* (2006) Pluripotency of spermatogonial stem cells from adult mouse testis. *Nature*, **440**, 1199–1203.
40. Takahashi, K. and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, **126**, 663–676.
41. Katkov, I.I., Kim, M.S., Bajpai, R., Altman, Y.S., Mercola, M., Loring, J.F., Terskikh, A.V., Snyder, E.Y. and Levine, F. (2006) Cryopreservation by slow cooling with DMSO diminished production of Oct-4 pluripotency marker in human embryonic stem cells. *Cryobiology*, **53**, 194–205.
42. Niwa, H., Miyazaki, J. and Smith, A.G. (2000) Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. *Nat. Genet.*, **24**, 372–376.